AMENDMENT TO INDEPENDENT DIRECTOR AGREEMENT

** **

This AMENDMENT TO INDEPENDENT DIRECTOR AGREEMENT (“Amendment”) is entered into as of August 10, 2026 (the “Amendment Date”), by and between Nano Nuclear Energy Inc. (the “Company”) and Diane Hare, an individual (the “Independent Director”).

WHEREAS, the Company and the Independent Director entered into that certain Independent Director Agreement, dated April 28, 2023 (the “Agreement”);

**WHEREAS, **pursuant to its terms, the Agreement expired on April 27, 2025;

WHEREAS, following the expiration of the Agreement, the Company and the Independent Director continued their relationship pursuant to the terms of the Agreement through their course of conduct without interruption, and now desire to memorialize such continuing relationship by extending the term of the Agreement and amending certain provisions of the Agreement as set forth herein; and

**WHEREAS, **the parties wish for the Agreement, as amended by this Amendment, to continue in full force and effect from and after April 27, 2025.

…

AMENDMENT TO INDEPENDENT DIRECTOR AGREEMENT

** **

This AMENDMENT TO INDEPENDENT DIRECTOR AGREEMENT (“Amendment”) is entered into as of August 10, 2026 (the “Amendment Date”), by and between Nano Nuclear Energy Inc. (the “Company”) and Kenny Yu, an individual (the “Independent Director”).

WHEREAS, the Company and the Independent Director entered into that certain Independent Director Agreement, dated May 8, 2023 (the “Agreement”);

**WHEREAS, **pursuant to its terms, the Agreement expired on May 7, 2025;

WHEREAS, following the expiration of the Agreement, the Company and the Independent Director continued their relationship pursuant to the terms of the Agreement through their course of conduct without interruption, and now desire to memorialize such continuing relationship by extending the term of the Agreement and amending certain provisions of the Agreement as set forth herein; and

**WHEREAS, **the parties wish for the Agreement, as amended by this Amendment, to continue in full force and effect from and after May 7, 2025.

…

AMENDMENT TO CONSULTING AGREEMENT

** **

This AMENDMENT TO CONSULTING AGREEMENT (“Amendment”) is entered into as of August 10, 2026 (the “Amendment Date”), by and between Nano Nuclear Energy Inc. (the “Company”) and Tsun Yee Law, an individual (the “Independent Director” or “Consultant”).

WHEREAS, the Company and the Independent Director entered into that certain Consulting Agreement, dated February 8, 2022 (the “Agreement”);

**WHEREAS, **pursuant to its terms, the Agreement expired on February 7, 2025;

WHEREAS, following the expiration of the Agreement, the Company and the Independent Director continued their relationship pursuant to the terms of the Agreement through their course of conduct without interruption, and now desire to memorialize such continuing relationship by extending the term of the Agreement and amending certain provisions of the Agreement as set forth herein; and

**WHEREAS, **the parties wish for the Agreement, as amended by this Amendment, to continue in full force and effect from and after February 7, 2025.

…

Certain identified information has been excluded from the exhibit by marking such portions with brackets (“[***]”) because it is both (i) not material and (ii) is the type of information that the registrant treats as private or confidential.

ROYALTY AND MILESTONE PAYMENT INTEREST PURCHASE AND SALE AGREEMENT

by and among

SPERO SPV, LLC,

as the Company,

THE ENTITIES MANAGED BY HEALTHCARE ROYALTY MANAGEMENT, LLC LISTED ON THE SIGNATURE PAGES HERETO, as the Purchasers

and

HCR SPERO SPV, LLC, as the Purchaser Representative

Dated July 8, 2026

---

TABLE OF CONTENTS

…

Termination Agreement

This Termination Agreement (“Agreement”) is entered into as of August 11, 2026 (the “Effective Date”) by and between:

EVEREST MEDICINES II LIMITED, a company incorporated under the laws of the Cayman Islands (“Everest”), with its registered office address at Vistra (Cayman) Limited, P.O. Box 31119, Grand Pavilion, Hibiscus Way, 802 West Bay Road, Grand Cayman, KY1-1205, Cayman Islands;

and

SPERO THERAPEUTICS, INC., a corporation organized under the laws of Delaware (“Spero”), with its principal place of business at 675 Massachusetts Avenue, 14th Floor, Cambridge, Massachusetts, 02139.

(Everest and Spero are each referred to herein as a “Party” and collectively as the “Parties”).

WHEREAS:

…

EXECUTIVE EMPLOYMENT AGREEMENT

This Executive Employment Agreement (this “Agreement”) is effective as of this 3rd day of August 2026 (the “Effective Date”) by and between Spero Therapeutics, Inc., a Delaware corporation (“Company”), and Debra Jeske Zack, MD, PhD (“Executive”).

WHEREAS, Executive and Company desire to set forth the terms and conditions for the employment of the Executive by the Company to assure the harmonious performance of the affairs of Company as well as to enter into a Proprietary Information and Inventions Assignment Agreement (the “Restrictive Covenant Agreement”).

NOW, THEREFORE, in consideration of the mutual promises, terms, provisions, and conditions contained herein, Company and Executive hereby agree as follows:

1.

…

Option No. _______

SPERO THERAPEUTICS, INC.

Stock Option Grant Notice

Stock Option Grant under the Company’s

2026 Stock Incentive Plan

1.	Name and Address of Participant:
2.	Date of Option Grant:
3.	Type of Grant:
4.	Maximum Number of Shares for which this Option is exercisable:

…

Certain identified information has been excluded from the exhibit by marking such portions with brackets (“[***]”) because it is both (i) not material and (ii) is the type of information that the registrant treats as private or confidential.

NEITHER THIS DEBT INSTRUMENT NOR THE NOTES ISSUED IN CONNECTION HEREWITH HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR ANY APPLICABLE STATE SECURITIES LAWS. SUCH SECURITIES HAVE BEEN ACQUIRED FOR INVESTMENT PURPOSES AND MAY NOT BE SOLD, OFFERED FOR SALE, PLEDGED OR HYPOTHECATED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT FILED UNDER SAID ACT AND ANY APPLICABLE STATE SECURITIES LAWS, UNLESS AN EXEMPTION FROM SUCH REGISTRATION IS AVAILABLE.

…

Certain identified information has been excluded from the exhibit by marking such portions with brackets (“[***]”) because it is both (i) not material and (ii) is the type of information that the registrant treats as private or confidential.

LIMITED RECOURSE GUARANTY

This LIMITED RECOURSE GUARANTY (this “Agreement”) dated as of July 8, 2026, is made by SPERO THERAPEUTICS, INC., a Delaware corporation (the “Guarantor”), in favor of HCR SPERO SPV, LLC, together with its successors and assigns, in its capacities as NPA Representative and RPA Representative for the benefit of the Note Purchasers and RPA Purchasers, respectively (in such capacities, the “Agent”). Capitalized terms used herein and not otherwise defined herein shall have the meanings set forth in the Note Purchase Agreement, Royalty Purchase Agreement or Issuer Contribution Agreement (each as defined below), as applicable; provided, that, if a term is defined in more than one such agreement, such term shall have the meaning assigned to it in the agreement expressly referenced herein or, if no agreement is expressly re

…

Restricted Stock Unit No.___________

SPERO THERAPEUTICS, INC.

Restricted Stock Unit Award Grant Notice

Restricted Stock Unit Award Grant under the Company’s

2026 Stock Incentive Plan

1.	Name and Address of Participant:

…

Certain identified information has been excluded from the exhibit by marking such portions with brackets (“[***]”) because it is both (i) not material and (ii) is the type of information that the registrant treats as private or confidential.

COLLABORATIONANDLICENSEAGREEMENT

byandamong

SPERO THERAPEUTICS, INC.,

INNOVENT BIOLOGICS (SUZHOU) CO., LTD.,

and

FORTVITA BIOLOGICS (USA), INC.

datedasof July 8,2026

---

TABLEOFCONTENTS

Article 1		DEFINITIONS	1
Article 2		GOVERNANCE	25
2.1		Alliance Managers	25
2.2		Committees	25

…

Exhibit 10.22.1

LONGEVERON INC.

AMENDMENT NO. 1 TO AT THE MARKET OFFERING AGREEMENT

June 16, 2026

H.C. Wainwright & Co., LLC

430 Park Avenue

New York, NY 10022 Ladies and Gentlemen:

Reference is made to the At the Market Offering Agreement, dated September 19, 2025 (the “SalesAgreement”), by and between Longeveron Inc., a Delaware corporation (the “Company”), and H.C. Wainwright & Co., LLC (the “Manager”). Capitalized terms used herein but not otherwise defined are used herein as defined in the Sales Agreement.

The Company and the Manager (collectively, the “Parties”) wish to amend the Agreement, to be effective as of the date hereof, pursuant to Section 14 of the Sales Agreement, on the terms and conditions set forth in this letter (this “Amendment”). Therefore, for and in consideration of the mutual covenants and agreements herein contained, and contained in the Sales Agreement, the Company, on the one hand, and the Manager, on the other hand, the Parties therefore hereby agree as follows:

1.

…